Overview

Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
In this protocol the investigators will test the effect of dalfampridine (a potassium channel blocker) on genioglossus muscle activity (EMG GG) during wakefulness and sleep in healthy control subjects.
Phase:
Phase 2
Details
Lead Sponsor:
Brigham and Women's Hospital
Treatments:
4-Aminopyridine